<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">najo</journal-id><journal-title-group><journal-title xml:lang="en">Nanosystems: Physics, Chemistry, Mathematics</journal-title><trans-title-group xml:lang="ru"><trans-title>Наносистемы: физика, химия, математика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2220-8054</issn><issn pub-type="epub">2305-7971</issn><publisher><publisher-name>Университет ИТМО</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17586/2220-8054-2022-13-3-342-348</article-id><article-id custom-type="elpub" pub-id-type="custom">najo-246</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Evaluation of antibacterial potential of bilirubin nanoparticles against Staphylococcus aureus and Escherichia coli</article-title><trans-title-group xml:lang="ru"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Kamothi</surname><given-names>D. J.</given-names></name></name-alternatives><email xlink:type="simple">kamothidhaval@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Kant</surname><given-names>V.</given-names></name></name-alternatives><email xlink:type="simple">drvinaykantluvas@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Kumar</surname><given-names>V.</given-names></name></name-alternatives><email xlink:type="simple">drvinodk10@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Joshi</surname><given-names>V. G.</given-names></name></name-alternatives><email xlink:type="simple">vinaygjoshi18@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Chhabra</surname><given-names>R.</given-names></name></name-alternatives><email xlink:type="simple">rchhabra59@rediffmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="en" id="aff-1"><institution>Lala Lajpat Rai University of Veterinary and Animal Sciences</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>06</day><month>06</month><year>2025</year></pub-date><volume>13</volume><issue>3</issue><fpage>342</fpage><lpage>348</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kamothi D.J., Kant V., Kumar V., Joshi V.G., Chhabra R., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Kamothi D.J., Kant V., Kumar V., Joshi V.G., Chhabra R.</copyright-holder><copyright-holder xml:lang="en">Kamothi D.J., Kant V., Kumar V., Joshi V.G., Chhabra R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nanojournal.ifmo.ru/jour/article/view/246">https://nanojournal.ifmo.ru/jour/article/view/246</self-uri><abstract><p>Antimicrobial resistance is a major emerging clinical and public health issue across the globe. Nanotechnology is an emerging eld and developing area of scienti c interest in the world. Earlier reports showed in vivo antibacterial activity of bilirubin. Therefore, in present study, bilirubin nanoparticles (BNP) were synthesized of ∼100 - 150 nm, spherical shape and negative charge. Antibacterial activity of BNPs at different concentrations (0.03, 0.1 and 0.3 %) was evaluated by agar well diffusion method against the gram-positive i.e. S. aureus and gram-negative i.e. E. coli bacteria. Tetracycline and enro oxacin used as positive control. Tetracycline and Enro oxacin at different concentrations exhibited zones of inhibition against both S. aureus and E. coli . However, BNPs as well as bulk bilirubin showed no in vitro antibacterial effect on S. aureus and E. coli , however, testing by broth method and at higher concentration as well as against other microorganisms can be explored in future.</p></abstract><kwd-group xml:lang="en"><kwd>Bilirubin nanoparticles</kwd><kwd>S. aureus</kwd><kwd>E. coli</kwd><kwd>antibacterial activity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. No. WHO/EMP/IAU/2017.11, World Health Organization, 2017.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. No. WHO/EMP/IAU/2017.11, World Health Organization, 2017.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aslam B., Wang W., et al. Antibiotic resistance: a rundown of a global crisis. Infect. Drug Resist., 2018, 11, P. 1645-1658.</mixed-citation><mixed-citation xml:lang="en">Aslam B., Wang W., et al. Antibiotic resistance: a rundown of a global crisis. Infect. Drug Resist., 2018, 11, P. 1645-1658.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y., Kim H., et al. Bilirubin nanoparticles as a nanomedicine for anti-in ammation therapy. Angew. Chem.Int. Ed., 2016, 55 (26), P. 7460-7463.</mixed-citation><mixed-citation xml:lang="en">Lee Y., Kim H., et al. Bilirubin nanoparticles as a nanomedicine for anti-in ammation therapy. Angew. Chem.Int. Ed., 2016, 55 (26), P. 7460-7463.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W. W., Smith D.L., Zucker, S. D. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology, 2004, 40 (2), P. 424-433.</mixed-citation><mixed-citation xml:lang="en">Wang W. W., Smith D.L., Zucker, S. D. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology, 2004, 40 (2), P. 424-433.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Santangelo R., Mancuso C., et al. Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro. Front. Pharmacol., 2012, 3, 36.</mixed-citation><mixed-citation xml:lang="en">Santangelo R., Mancuso C., et al. Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro. Front. Pharmacol., 2012, 3, 36.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Buyukasik Y., Akman U., et al. Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilbert’s syndrome. Am. J. Med. Sci., 2008, 335, P. 115-119.</mixed-citation><mixed-citation xml:lang="en">Buyukasik Y., Akman U., et al. Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilbert’s syndrome. Am. J. Med. Sci., 2008, 335, P. 115-119.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Terzi H.A., Kardes H., et al. The antibacterial effects of bilirubin on gram-negative bacterial agents of sepsis. Biomed. Res., 2016, 27, P. 207-209.</mixed-citation><mixed-citation xml:lang="en">Terzi H.A., Kardes H., et al. The antibacterial effects of bilirubin on gram-negative bacterial agents of sepsis. Biomed. Res., 2016, 27, P. 207-209.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Perez C., Pauli M., Bazerque P. An antibiotic assay by agar-well diffusion method. Acta Biol. Med. Exp., 1990, 15, P. 113-115.</mixed-citation><mixed-citation xml:lang="en">Perez C., Pauli M., Bazerque P. An antibiotic assay by agar-well diffusion method. Acta Biol. Med. Exp., 1990, 15, P. 113-115.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kamothi D.J., Kant V., et al. Novel preparation of bilirubin-encapsulated pluronic F-127 nanoparticles as a potential biomaterial for wound healing. Eur. J. Pharmacol., 2022, 919, 174809.</mixed-citation><mixed-citation xml:lang="en">Kamothi D.J., Kant V., et al. Novel preparation of bilirubin-encapsulated pluronic F-127 nanoparticles as a potential biomaterial for wound healing. Eur. J. Pharmacol., 2022, 919, 174809.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shaarani S., Hamid S.S., Mohd Kaus N.H. The In uence of Pluronic F68 and F127 Nanocarrier on Physicochemical Properties, In vitro Release, and Antiproliferative Activity of Thymoquinone Drug. Pharmacogn. Res., 2017, 9 (1), P. 12-20.</mixed-citation><mixed-citation xml:lang="en">Shaarani S., Hamid S.S., Mohd Kaus N.H. The In uence of Pluronic F68 and F127 Nanocarrier on Physicochemical Properties, In vitro Release, and Antiproliferative Activity of Thymoquinone Drug. Pharmacogn. Res., 2017, 9 (1), P. 12-20.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lanone S., Bloc S., et al. Bilirubin decreases nos2 expression via inhibition of NAD (P) H oxidase: implications for protection against endotoxic shock in rats. Faseb J., 2005, 19 (13), P. 1890-1892.</mixed-citation><mixed-citation xml:lang="en">Lanone S., Bloc S., et al. Bilirubin decreases nos2 expression via inhibition of NAD (P) H oxidase: implications for protection against endotoxic shock in rats. Faseb J., 2005, 19 (13), P. 1890-1892.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen R., Gibson S., et al. Adaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin. Sci. Rep., 2018, 8 (1), 6470.</mixed-citation><mixed-citation xml:lang="en">Hansen R., Gibson S., et al. Adaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin. Sci. Rep., 2018, 8 (1), 6470.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
